10th Conference on Retroviruses and Opportunistic Infections (CROI), 10-14 February 2003, Boston, USA
1 April 2003. Related: Conference reports, Conference index, CROI 10 (Retrovirus) 2003.
The 10th Conference on Retroviruses and Opportunistic Infections (CROI) was held from 10-14 February in Boston, USA, and was attended by nearly 4,000 delegates. This conference is one of the most important annual scientific HIV meetings.
Abstracts, including all abstracts referred to in references to the following reports, as well as many of the full posters, and webcasts from the symposium sessions and special lectures together with accompanying slides, are available at:
http://www.retroconference.org/2003/
The following articles are included in coverage of this conference.
Antiretrovirals
- Pipeline compounds in Phase 2/3 studies
- 96-week results show tenofovir-including regimen has side-effect advantages over d4T regimen in treatment naïve patients
- 2NN results – nevirapine and efavirenz in prospective randomised head-to-head study
- NIH/NIAID study of generic drugs shows results consistent with stringent manufacturing standards
Treatment Strategies
Women’s Studies
Side Effects
- Tenofovir and renal tubular dysfunction
- Approaches to treatment of lipodystrophy
- Surgery for buffalo hump shows variable results depending on method
- Other studies – nucleosides and switching to abacavir; importance of lipoatrophy and buffalo hump
- HAART to HEART: cardiovascular risk in HIV
- Alendronate, vitamin D and calcium are safe and effective treatment for HIV-associated bone loss
- Bone loss and fat loss are closely related in HIV patients on HAART
Hepatitis Coinfection:
- Low dose 200/100 IDV/RTV managed by TDM in substudy of co-infected patients
- 12-week response predicts which HIV-HCV coinfected patients will not benefit from continued pegylated interferon plus ribavirin
- Pegylated interferon associated with eye disorders
Resistance: